🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FDA approves KalVista's Ekterly for #hereditary #angioedema: Ekterly’s efficacy was demonstrated through data from KalVista’s Phase III KONFIDENT clinical trial. pharmaceutical-technology.com/news/fda-kalvi…

#Biosimilars: A Healio Guide for Clinicians. This Special Report breaks down everything the practicing clinician needs to know about biosimilars – what they are, how they are approved, where interchangeable medications fit in, and more. healio.com/special-report…

Prevalence trends and risk factors for #allergic #rhinoconjunctivitis, #asthma and #eczema in the UK. Open Access. ivancevichmd.blogspot.com/2025/07/preval…

GINA is happy to announce the 2025 Summary Guide is now available! Visit bit.ly/44GpR6z to view or purchase the GINA 2025 Summary Guide today.

Dear Colleagues, Thank you for attending the #WorldAllergyWeek2025 webinar on “#Anaphylaxis: A Preventable Threat”. Link to Webinar Evaluation: surveymonkey.com/r/WorldAllergy…

Allergic to the sun? Henry Lim, MD explains polymorphous light eruption healio.com/news/dermatolo…

Comparing #allergic #rhinitis treatments based on patient satisfaction: A #MASK-air® study. Open Access. jaci-inpractice.org/article/S2213-…

#Allergy-related #skin diseases are frequent in children and often pose significant diagnostic and management challenges. Pediatric Allergy and Immunology has recently published a significant number of important contributions addressing this complex field. onlinelibrary.wiley.com/doi/toc/10.111…

#Endotypes in Immune Mediated #Drug #Reactions: Present and Future of Relevant #Biomarkers. An EAACI Task Force Report. Open Access. ivancevichmd.blogspot.com/2025/07/endoty…

Patterns of #Respiratory #Symptoms and #Asthma #Diagnosis in School-Age Children: Three Birth Cohorts. Open Access. interasma.org/2025/07/10/pat…

Comparison of three treatment strategies in mild #asthma: A carbon-utility analysis. Findings indicate that as-needed #budesonide/#formoterol DPI is the preferred option when considering both carbon emissions and #treatment effectiveness. jaci-inpractice.org/article/S2213-…

#Eosinophilic #gastrointestinal diseases are exponentially more prevalent among patients with #atopic diseases compared with the general population, according to a study published in Annals of #Allergy, #Asthma & #Immunology. healio.com/news/allergy-a…

#WAOJournal: #Artificial #intelligence in #allergy practice: Digital transformation and the future of clinical care. Open Access. sciencedirect.com/science/articl…

Patients with #asthma and #allergic #bronchopulmonary #aspergillosis experienced improvements with #dupilumab, according to data presented at the American Thoracic Society International Conference. healio.com/news/allergy-a…

The #FDA has approved #garadacimab-gxii for prophylactic use in patients aged 12 years and older with #hereditary #angioedema, according to a press release from CSL Behring. healio.com/news/allergy-a…

Beneath the Surface: How to treat #itch with the latest #therapeutics. Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options that target the source of their itch. healio.com/news/dermatolo…

A 10-year-old boy presented for evaluation of “itchy bumps” on the arms and legs over several months. The exam shows erythematous papules and vesicles on the upper and lower extremities, along with scattered crusted lesions and hypopigmented ring lesions medscape.com/viewarticle/10…

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study. medscape.com/viewarticle/du…

Scientists on a quest to prevent #asthma by boosting #immune #system: University of Arizona Health Sciences researchers are testing #Broncho-Vaxom® in children to see if it can stop asthma before symptoms ever appear. healthsciences.arizona.edu/news/stories/s…

'Molecular shield' placed in the nose may soon treat common hay fever trigger: a monoclonal antibody designed to block a specific pollen allergen has been delivered directly into the nose to protect against allergy symptoms in the upper and lower airways. medicalxpress.com/news/2025-07-m…